Policy | April 10, 2026
NITI Aayog releases reports to improve ease of doing R&D in India
The reports will now be shared with relevant ministries and departments as a guidance framework
The reports will now be shared with relevant ministries and departments as a guidance framework
For the biopharma industry, the study strengthens the case for balancing immune-cell engagement with tolerability in antibody discovery platforms
Scholarships, research grants and industry mentorship framework aim to strengthen India’s pharma R&D ecosystem
Discussions are likely to centre on how the country can move up the pharmaceutical value chain
Biopharma companies face persistent hurdles in cell line development, including long timelines, low yields, and high failure rates for novel molecules
The new capital is expected to fund the company through 2029
Under the collaboration, Symeres will test Ambagon’s newly designed molecular glues using in vitro assays and mechanistic studies
As demand for GLP-1 therapies explodes, India’s drug regulator moves to curb advertising amid rising concerns over misuse, access, and long-term impact
Multi-year CDMO partnership combines AI-led virtual development, precision chemistry and GMP manufacturing to accelerate five high-science APIs across regulated markets
MoU to deploy Qure.ai’s chest X-ray solution across 20 government facilities aims to improve early detection in urban and rural populations
Subscribe To Our Newsletter & Stay Updated
